Micro RNA 155 and Its Target Gene CTLA4 as a New Biomarker for Lymphocyte Activation in HCV-Induced Liver Fibrosis and Hepatocellular Carcinoma

Theodor Bilharz Research Institute

Bibliographic Information

Authors: Amin N.A.; El-Araby R.E.; Abo El Nil O.B.; Osman R.A.; Ragab K.M.; Hassan A.S.M.

Journal: Egyptian Journal of Chemistry

Publisher: National Information and Documentation Centre

Publication Date: 1 December 2024

Volume / Issue: Volume 67 / Issue 12

Pages: 327–336

ISSN: 4492285

DOI: 10.21608/ejchem.2024.318046.10338

Scopus: View on Scopus

Document Type: Article

Access: All Open Access; Bronze Open Access


Authors and Affiliations

Amin N.A., Haematolog Department, Theodor Bilharz Research Institute, P.O. 30, Giza, 12411, Egypt; El-Araby R.E., Central Lab, Theodor Bilharz Research Institute, P.O. 30, Giza, 12411, Egypt; Abo El Nil O.B., Haematolog Department, Theodor Bilharz Research Institute, P.O. 30, Giza, 12411, Egypt; Osman R.A., Clinical Pathology Department, National Cancer Institute, Cairo, Egypt; Ragab K.M., HepatoGastroenterology Department, Theodor Bilharz Research Institute, P.O. 30, Giza, 12411, Egypt; Hassan A.S.M., Electron Microscopy Department, Theodor Bilharz Research Institute, P.O. 30, Giza, 12411, Egypt


Abstract

The role of microRNA 155 (miRNA 155) and the immunological checkpoint cytotoxic T-lymphocyte associated antigen 4 (CTLA-4) in chronic liver diseases and hepatocellular carcinoma (HCC) are complex. The alterations in the expression levels or functions of CTLA-4 and miRNA 155 could influence the outcome of HCV infection by affecting the quality and persistence of the antiviral immune response. Here, we tried to investigate the relationships of miRNA 155 gene expression with CTLA-4, the regulator gene of lymphocyte activation in patients with HCC and chronic HCV infection to assess the interactions between these genes and lymphocyte activation and its contribution in liver disease progression. A case-control study included 80 subjects (20 healthy controls, 20 HCV patients without cirrhosis, 20 with liver cirrhosis, and 20 patients with HCC). The expression of miRNA 155 and CTLA-4 gene were measured by quantitative real-time qRT-PCR. The percentage of circulating regulatory T (T reg) cells expressing CD4 and CD25 was done by flow cytometry. Results revealed that miRNA 155 and CTLA-4 gene were upregulated with higher expression in HCC and liver cirrhosis patients compared to HCV without liver cirrhosis and control groups (p value < 0.05). Together with a significant increase in CD4+CD25+ T reg in HCC and liver cirrhosis patients compared to the HCV group (p value <0.05). In conclusion, miRNA 155 and CTLA-4 gene could be utilized as new biomarkers in HCV- induced liver fibrosis and HCC for further exploration of immunomodulatory strategies targeting these molecules to enhance antiviral immune responses and prevent hepatocarcinogenesis. ©2024 National Information and Documentation Center (NIDOC)


Keywords

CTLA-4; HCC; Liver cirrhosis; Micro RNA 155; T lymphocytes


Citation Information

Scopus Citations: 0


For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.

The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.

English Website: https://www.tbri.sci.eg/en/

Arabic Website: https://www.tbri.sci.eg/ar/

Prepared and Uploaded by:

Abdalla F. Abdalla

Electronic Portal Unit

Electronic Portal Unit

Popular Posts

A cost-performance index for nano-optical biosensor evaluation: Systematic evaluation of europium–salicylate luminescent platforms for GPC3-targeted early HCC diagnosis

Interpretation of liver stiffness measurement in patients with mixed liver disease etiologies

Multifunctional polycaprolactone-based composite fibers with icariin and glutathione for effective repair of critical-sized bone defects

Holothuria arenicola Extract-Loaded Polycaprolactone Nanocapsules Attenuate Bile Duct Ligation-Induced Acute Liver Injury

Mytilus edulis-mediated green synthesis of selenium nanoparticles with antimicrobial and molluscicidal applications

Microbial levan potentiates hepatic retention and antitumor activity of a PEGylated benzimidazole–curcumin nanocomplex through TLR2–FXR/FGF15-associated immunometabolic remodeling in experimental liver cancer

Variable clinical presentations of pulmonary hydatid cysts: a four-case series from a single center in United Arab Emirates, non-endemic region